These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 30209787)

  • 1. Using pH Gradient Dissolution with In-Situ Flux Measurement to Evaluate Bioavailability and DDI for Formulated Poorly Soluble Drug Products.
    Li J; Tsinman K; Tsinman O; Wigman L
    AAPS PharmSciTech; 2018 Oct; 19(7):2898-2907. PubMed ID: 30209787
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of Microenvironmental pH Modulation on the Dissolution Rate and Oral Absorption of the Salt of a Weak Acid - Case Study of GDC-0810.
    Hou HH; Jia W; Liu L; Cheeti S; Li J; Nauka E; Nagapudi K
    Pharm Res; 2018 Jan; 35(2):37. PubMed ID: 29380076
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of food and the proton pump inhibitor rabeprazole on the pharmacokinetics of GDC-0941 in healthy volunteers: bench to bedside investigation of pH-dependent solubility.
    Ware JA; Dalziel G; Jin JY; Pellett JD; Smelick GS; West DA; Salphati L; Ding X; Sutton R; Fridyland J; Dresser MJ; Morrisson G; Holden SN
    Mol Pharm; 2013 Nov; 10(11):4074-81. PubMed ID: 24099279
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics and absorption of the anticancer agents dasatinib and GDC-0941 under various gastric conditions in dogs--reversing the effect of elevated gastric pH with betaine HCl.
    Pang J; Dalziel G; Dean B; Ware JA; Salphati L
    Mol Pharm; 2013 Nov; 10(11):4024-31. PubMed ID: 23980865
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro dissolution methodology, mini-Gastrointestinal Simulator (mGIS), predicts better in vivo dissolution of a weak base drug, dasatinib.
    Tsume Y; Takeuchi S; Matsui K; Amidon GE; Amidon GL
    Eur J Pharm Sci; 2015 Aug; 76():203-12. PubMed ID: 25978875
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In Vitro Dissolution of Fluconazole and Dipyridamole in Gastrointestinal Simulator (GIS), Predicting in Vivo Dissolution and Drug-Drug Interaction Caused by Acid-Reducing Agents.
    Matsui K; Tsume Y; Amidon GE; Amidon GL
    Mol Pharm; 2015 Jul; 12(7):2418-28. PubMed ID: 25985298
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of a Physiologically Relevant Population Pharmacokinetic in Vitro-in Vivo Correlation Approach for Designing Extended-Release Oral Dosage Formulation.
    Kim TH; Shin S; Bulitta JB; Youn YS; Yoo SD; Shin BS
    Mol Pharm; 2017 Jan; 14(1):53-65. PubMed ID: 27809538
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biorelevant Dissolution Models for a Weak Base To Facilitate Formulation Development and Overcome Reduced Bioavailability Caused by Hypochlordyria or Achlorhydria.
    Kou D; Dwaraknath S; Fischer Y; Nguyen D; Kim M; Yiu H; Patel P; Ng T; Mao C; Durk M; Chinn L; Winter H; Wigman L; Yehl P
    Mol Pharm; 2017 Oct; 14(10):3577-3587. PubMed ID: 28834434
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessing Supersaturation and Its Impact on In Vivo Bioavailability of a Low-Solubility Compound ABT-072 With a Dual pH, Two-Phase Dissolution Method.
    Shi Y; Erickson B; Jayasankar A; Lu L; Marsh K; Menon R; Gao P
    J Pharm Sci; 2016 Sep; 105(9):2886-2895. PubMed ID: 27321234
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Utilization of In Vitro, In Vivo and In Silico Tools to Evaluate the pH-Dependent Absorption of a BCS Class II Compound and Identify a pH-Effect Mitigating Strategy.
    Gesenberg C; Mathias NR; Xu Y; Crison J; Savant I; Saari A; Good DJ; Hemenway JN; Narang AS; Schartman RR; Zheng N; Buzescu A; Patel J
    Pharm Res; 2019 Oct; 36(12):164. PubMed ID: 31637544
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Application of a Novel 'Make and Test in Parallel' Strategy to Investigate the Effect of Formulation on the Pharmacokinetics of GDC-0810 in Healthy Subjects.
    Cheeti S; Hou HH; Nelson E; Walker H; Chen B; Morley R; Gates M; Musib L; Girish S; Sahasranaman S; Liu L
    Pharm Res; 2018 Oct; 35(12):233. PubMed ID: 30324422
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oral formulations of adefovir dipivoxil: in vitro dissolution and in vivo bioavailability in dogs.
    Cundy KC; Sue IL; Visor GC; Marshburn J; Nakamura C; Lee WA; Shaw JP
    J Pharm Sci; 1997 Dec; 86(12):1334-8. PubMed ID: 9423141
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Utilizing In Vitro Dissolution-Permeation Chamber for the Quantitative Prediction of pH-Dependent Drug-Drug Interactions with Acid-Reducing Agents: a Comparison with Physiologically Based Pharmacokinetic Modeling.
    Zhu AZ; Ho MD; Gemski CK; Chuang BC; Liao M; Xia CQ
    AAPS J; 2016 Nov; 18(6):1512-1523. PubMed ID: 27600136
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Formulation of solid dosage forms to overcome gastric pH interaction of the factor Xa inhibitor, BMS-561389.
    Badawy SI; Gray DB; Zhao F; Sun D; Schuster AE; Hussain MA
    Pharm Res; 2006 May; 23(5):989-96. PubMed ID: 16715389
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Classification of torasemide based on the Biopharmaceutics Classification System and evaluation of the FDA biowaiver provision for generic products of CLASS I drugs.
    Khan MZ; Rausl D; Radosević S; Filić D; Danilovski A; Dumić M; Knezević Z
    J Pharm Pharmacol; 2006 Nov; 58(11):1475-82. PubMed ID: 17132210
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In Vitro-In Vivo Predictive Dissolution-Permeation-Absorption Dynamics of Highly Permeable Drug Extended-Release Tablets via Drug Dissolution/Absorption Simulating System and pH Alteration.
    Li ZQ; Tian S; Gu H; Wu ZG; Nyagblordzro M; Feng G; He X
    AAPS PharmSciTech; 2018 May; 19(4):1882-1893. PubMed ID: 29663288
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dynamic dissolution testing to establish in vitro/in vivo correlations for montelukast sodium, a poorly soluble drug.
    Okumu A; DiMaso M; Löbenberg R
    Pharm Res; 2008 Dec; 25(12):2778-85. PubMed ID: 18560996
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predicting in vivo absorption behavior of oral modified release dosage forms containing pH-dependent poorly soluble drugs using a novel pH-adjusted biphasic in vitro dissolution test.
    Heigoldt U; Sommer F; Daniels R; Wagner KG
    Eur J Pharm Biopharm; 2010 Sep; 76(1):105-11. PubMed ID: 20472059
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In Vitro, in Silico, and in Vivo Assessments of Intestinal Precipitation and Its Impact on Bioavailability of a BCS Class 2 Basic Compound.
    Kou D; Zhang C; Yiu H; Ng T; Lubach JW; Janson M; Mao C; Durk M; Chinn L; Winter H; Wigman L; Yehl P
    Mol Pharm; 2018 Apr; 15(4):1607-1617. PubMed ID: 29522347
    [TBL] [Abstract][Full Text] [Related]  

  • 20. GDC-0810 Pharmacokinetics and Transporter-Mediated Drug Interaction Evaluation with an Endogenous Biomarker in the First-in-Human, Dose Escalation Study.
    Cheung KWK; Yoshida K; Cheeti S; Chen B; Morley R; Chan IT; Sahasranaman S; Liu L
    Drug Metab Dispos; 2019 Sep; 47(9):966-973. PubMed ID: 31266752
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.